The new ready-to-use products offer significant improvement in data quality for 2-D electrophoresis experiments, and also reduce costs and time for protein expression analysis (at least a threefold cost saving and sixfold time saving with 2-D DIGE). The products are designed to be used individually or as a complete solution to maximize results from 2-D analysis and are also fully compatible with 2–D DIGE (Difference Gel Electrophoresis).
“We have worked to identify and address the challenges that our customers face in 2-D electrophoresis. Most of them relate to unwanted sources of experimental variation,” said Rita Marouga, Product Manager, GE Healthcare. “These new products are designed specifically to improve consistency and reduce heterogeneity throughout the 2-D workflow, thereby enabling identification of differences and changes in protein expression attributable to biological variation with high confidence.”
The new products include: precast low fluorescent DIGE Gels and DIGE Buffer Kit that improve gel-to-gel reproducibility; repackaged CyDye™ DIGE Fluor saturation and minimal dyes that better suit experimental designs; and reformulated IPG Buffer and IPG strips (Immobiline™ DryStrip gels) that improve spot resolution. These augment the previously released 2-D Protein Extraction Buffers, IPGbox and DeCyder 2-D v7 software that contribute to error reduction and optimization of the results in the 2-D experimental workflow.
All of the 2-D electrophoresis products from GE Healthcare have been tested together through the development process, and combine to provide a synchronized solution for 2-D analysis where sources of variation are minimized or eliminated throughout the workflow.
For more information please visit: www.gelifesciences.com/2DE
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.
GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 47,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
